Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Olumiant ® (baricitinib)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Olumiant® (baricitinib): Risk and Comorbid COVID-19 in Rheumatoid Arthritis Patients
Eli Lilly and Company has not studied the use of baricitinib in patients with rheumatoid arthritis and COVID-19 nor in rheumatoid arthritis patients at risk of contracting COVID-19.
UK_cFAQ_BAR089A_COMORBID_RISK_COVID-19_RA
en-GB
Baricitinib and COVID-19
Baricitinib is not approved for the treatment of COVID-19, COVID-19 pneumonia, or COVID-19. Please see local labeling for approved indications.
COVID-19 Risk or Prevention in Patients with Rheumatoid Arthritis Treated with Baricitinib
Although BARI is being studied for the treatment of COVID-19, it is unknown if patients treated with baricitinib for rheumatoid arthritis are at a greater risk of both contracting COVID-19 and having COVID-19 related complications.
Clinical Registry Data for Patients With Rheumatological Disorders and COVID-19
Clinical registries have been formed to collect data from patients with rheumatic diseases and COVID-19. These registries have assessed baseline medications for rheumatoid arthritis as well as COVID-19 clinical outcomes.1-6
To date, publications from these registries have reported an insufficient volume of patients treated with JAK inhibitors, including BARI, to draw conclusions regarding risk of contracting COVID-19, risk for COVID-19 related complications or any potential protective effect of JAK inhibitors.2,4-7
Risks and Outcomes of COVID-19 in the Autoimmune Population
Analyses on the risks and outcomes of COVID-19 in patients with autoimmune disease, including rheumatoid arthritis, have been published. Please see references for relevant citations.8-11
Efficacy and Safety of Baricitinib in Patients With Rheumatoid Arthritis and COVID-19
An analysis of the efficacy and safety of baricitinib in patients with RA and COVID-19 has not been conducted.
Baricitinib Infection-Related Warnings and Precautions
COVID-19 is an active respiratory disease, which is typically mild but may lead to acute respiratory distress syndrome which can be lethal. Please note the important BARI infection-related warnings and precautions listed below for consideration.
Baricitinib is associated with an increased rate of infections such as upper respiratory tract infections compared to placebo. In rheumatoid arthritis clinical studies, in treatment naïve patients, combination with methotrexate resulted in increased frequency of infections compared to baricitinib monotherapy.12
The risks and benefits of treatment with baricitinib should be carefully considered prior to initiating therapy in patients with active, chronic or recurrent infections.12
If an infection develops, the patient should be monitored carefully and baricitinib therapy should be temporarily interrupted if the patient is not responding to standard therapy. Baricitinib treatment should not be resumed until the infection resolves.12
Incidence of Infections in Baricitinib Clinical trials
Upper Respiratory Tract Infections
Upper respiratory tract infections were very commonly (≥10%) reported adverse events in RA BARI clinical trials.13
|
7-Study Dataseta |
||
n (EAIR) |
Placebo |
BARI 2 mg |
BARI 4 mg |
All TE Infection |
340 (75.4) |
156 (84.0) |
423 (89.7) |
Upper Respiratory Tract Infectionsb |
184 (40.8) |
91 (49.0) |
224 (47.5) |
Abbreviations: BARI = baricitinib; EAIR = exposure adjusted incidence rate; IR = incidence rate; PYE = patient-years of exposure; TE = treatment emergent.
aThe 7-study pooled dataset included patients with RA randomized to BARI 4 mg (N=1142, PYE=471.8) or placebo (N=1215, PYE=450.8) from 3 phase 2 studies and 4 phase 3 studies. Patients in the placebo group could have been taking background MTX or other conventional DMARDs. Data from BARI 2 mg (N=479, PYE=185.8) is derived from 4 of these studies in which both BARI 2 mg and BARI 4 mg were options during randomization.
bIncludes acute sinusitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinusitis, sinobronchitis, tonsillitis, tracheitis, and upper respiratory tract infection.
Serious Infections in Rheumatoid Arthritis Clinical Trials
The All BARI RA analysis set included 3770 patients with RA who received BARI at a variety of doses from 1 phase 1, 3 phase 2, and 5 phase 3 studies (RA-BEGIN, RA-BEAM, RA-BUILD, RA-BEACON, RA-BALANCE). Data includes a long-term extension study (RA-BEYOND) with
Of the 3770 patients who received BARI in the RA clinical trials through 13 February 2018, there were 283 TE serious infections with an IR per 100 PYE, censored at time of event, of 2.8. The most frequent serious infections reported were
- pneumonia (n=52, EAIR 0.5)
- HZ (n=35, EAIR 0.4)
- urinary tract infection (n=21, EAIR 0.2)
- cellulitis (n=15, EAIR 0.2)
- sepsis (n=18 including 14 cases of sepsis and 4 cases of urosepsis), and
- gastroenteritis (n=13, EAIR 0.13).13-15
Clinical Factors Associated with Serious Infection
A large group of clinical factors with the potential to affect the risk of serious infection was evaluated using Cox models and data from the All BARI RA dataset through 01 January 2016. The 5 independent risk factors identified for serious infection were
- prior biologic use
- advanced age
- Asian region of study enrollment, excluding Japan
- non-normal body mass index, and
- concomitant corticosteroid use.3
Additionally, increasing grades of lymphopenia were associated with an increase in frequency of any TE infection and serious infection in BARI-treated patients.13
Clinical Use
The treating physician may use the information provided, the patient’s prior medical history and concomitant medications, and other individual factors, in formulating an assessment and approach. The treating physician should consider potential risks and benefits of treatment options, and monitor appropriately.
Infectious Disease Resources
For the most current information regarding COVID-19, please refer to the WHO, ECDC and EULAR websites:
- World Health Organization at https://www.who.int/emergencies/diseases/novel-coronavirus-2019
- European Centre for Disease Prevention and Control at https://www.ecdc.europa.eu/en/covid-19-pandemic and
- European League Against Rheumatism at https://www.eular.org/rheumatism_and_covid_19.cfm
For current NICE guidance, please refer to 'COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders' at www.nice.org.uk/guidance/ng167.
References
1Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. Published online May 29, 2020. http://dx.doi.org/10.1136/annrheumdis-2020-217871
2Gianfrancesco MA, Hyrich KL, Gossec L, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. Published online April 16, 2020. https://doi.org/10.1016/S2665-9913(20)30095-3
3Winthrop KL, Genovese MC, Harigai M, et al. Serious infection and associated risk factors in patients with moderate to severe rheumatoid arthritis treated with baricitinib [abstract OP0248]. Ann Rheum Dis. 2017;76(suppl 2):158. http://ard.bmj.com/content/76/Suppl_2/158.2
4Scirè CA, Carrara G, Zanetti A, et al. Italian Registry of the Italian Society for Rheumatology (CONTROL-19). COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19). Clin Exp Rheumatol. 2020 Jul-Aug;38(4):748-753. https://www.clinexprheumatol.org/article.asp?a=15906
5Michaud K, Wipfler K, Shaw Y, et al. Experiences of Patients With Rheumatic Diseases in the United States During Early Days of the COVID-19 Pandemic. ACR Open Rheumatol. 2020 Jun;2(6):335-343. https://doi.org/10.1002/acr2.11148
6Hasseli R, Mueller-Ladner U, Schmeiser T, et al. National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD. RMD Open. 2020;6:e001332. http://dx.doi.org/10.1136/rmdopen-2020-001332
7Winthrop KL, Brunton AE, Beekmann S, et al. SARS CoV-2 infection among patients using immunomodulatory therapies. Ann Rheum Dis. Published online August 5, 2020. http://dx.doi.org/10.1136/annrheumdis-2020-218580
8Freites Nuñez DD, Leon L, Mucientes A, et al. Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases. Annals of the Rheumatic Diseases 2020;79(11):1393-9. https://www.doi.org/10.1136/annrheumdis-2020-217984
9Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systemic review and meta-analysis. Ann Rheum Dis. 2020. http://dx.doi.org/10.1136/annrheumdis-2020-218946
10Favalli EG, Monti S, Ingegnoli F, et al. Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheum. 2020;72(10):1600-1606. http://dx.doi.org/10.1002/art.41388
11Haberman RH, Castillo R, Chen A, et al. COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and DMARDs on clinical outcomes. Arthritis Rheumatol. 2020. http://dx.doi.org/10.1002/art.41456
12Olumiant [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
13Data on file, Eli Lilly and Company and/or one of its subsidiaries.
14Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 7 years: an updated integrated safety analysis. Ann Rheum Dis. 2019;78(2):308-309. http://dx.doi.org/10.1136/annrheumdis-2019-eular.691
15Genovese MC, Smolen JS, Takeuchi T, et al. Safety profile of baricitinib for the treatment of rheumatoid arthritis up to 7 years: an updated integrated safety analysis. Presented as an oral presentation at: European League Against Rheumatism (EULAR) Annual Meeting; June 12-15, 2019; Madrid, Spain.
Glossary
BARI = baricitinib
COVID-19 = coronavirus disease 2019
EAIR = exposure-adjusted incidence rate
ECDC = European Center for Disease Prevention and Control
EULAR = European League Against Rheumatism
JAK = Janus kinase
PYE = patient-years of exposure
RA = rheumatoid arthritis
TE = treatment-emergent
US = United States
WHO = World Health Organization
Date of Last Review: 19 November 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays